23 May 2023
Ondine Biomedical Inc.
("Ondine Biomedical", "Ondine" or the "Company")
Annual Report for the Year Ended 31 December 2022
Ondine Biomedical (AIM: OBI) announces that its Annual Report for the year ended 31 December 2022 was posted on 23 May 2022 and is available on the Ondine website at: https://ondinebio.com/investors/reports-documentation/
| Ondine Biomedical Inc. |
|
| Angelika Vance, Corporate Communications | +001 (1) 604 838 2702 |
|
|
|
| Singer Capital Markets (Nominated Adviser and Joint Broker) |
|
| Aubrey Powell, Asha Chotai, Sam Butcher | +44 (0)20 7496 3000 |
|
|
|
| RBC Capital Markets (Joint Broker) |
|
| Rupert Walford, Kathryn Deegan | +44 (0) 20 7653 4000 |
|
|
|
| Vane Percy & Roberts (Media Contact) |
|
| Simon Vane Percy, Amanda Bernard | +44 (0) 77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave™. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.